Make an appointment with a cancer specialist today.
Call us at 800-KARMANOS (800-527-6266)


Karmanos' pancreatic cancer expert co-authors study exploring combinational therapy

Philip A. Philip, M.D., Ph.D., FRCP, multidisciplinary team leader of Gastrointestinal Oncology and professor of Medicine and Oncology at the Barbara Ann Karmanos Cancer Institute, is the principal investigator and lead author of a study that has recently been published in the Journal of Clinical Oncology (JCO).
The original report is entitled, “Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients with Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group-Directed Intergroup Trial S0205.”
The national study, the largest of its kind, accrued a total of 745 eligible patients with locally-advanced or metastatic pancreas cancer. Dr. Philip mentioned that the study accrued patients faster than researchers expected.
Research was conducted to evaluate the contribution of cetuximab, an EGFR-targeted agent, when combined with standard gemcitabine therapy. Learning whether cetuximab provides therapeutic benefits has been a major scientific goal in the cancer research community, according to Dr. Philip.
Results showed that no significant difference was seen between the two arms of the study – one that used gemcitabine alone and the second that combined gemcitabine and cetuximab – with respect to median survival time. Furthermore, the time lapsed before treatment failure was longer in patients on both drugs, but only by two weeks. Among patients who were studied for tumoral EGFR expression, 90 percent were positive, with no treatment benefit detected in the combination treatment subset group.
Dr. Philip shares authorship with Jacqueline Benedetti, Christopher L. Corless, Ralph Wong, Eileen M. O’Reilly, Patrick J. Flynn, Kendrith M. Rowland, James N. Atkins, Barry C. Mirtsching, Saul E. Rivkin, Alok A. Khorana, Bryan Goldman, Cecilia M. Fenoglio-Preiser, James L. Abbruzzese and Charles D. Blancke.
Please join us in congratulating Dr. Philip on his recent publication in JCO.
To read more about the study, please click here:
© 2014 Karmanos Cancer Institute Pencil
The Barbara Ann Karmanos Cancer Center is accredited by The Joint Commission.
If members of the public have any quality-of-care or safety concerns, they may notify The Joint Commission at 630-792-5800.